Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC decreased its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 2.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 38,222 shares of the biopharmaceutical company’s stock after selling 796 shares during the quarter. HighTower Advisors LLC’s holdings in Dynavax Technologies were worth $488,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Wealthfront Advisers LLC purchased a new position in Dynavax Technologies during the fourth quarter valued at $193,000. AlphaQuest LLC boosted its position in shares of Dynavax Technologies by 10.2% during the 4th quarter. AlphaQuest LLC now owns 23,437 shares of the biopharmaceutical company’s stock valued at $299,000 after acquiring an additional 2,172 shares during the last quarter. Amundi raised its stake in Dynavax Technologies by 172.6% during the fourth quarter. Amundi now owns 58,896 shares of the biopharmaceutical company’s stock worth $743,000 after purchasing an additional 37,290 shares during the period. E Fund Management Co. Ltd. increased its holdings in shares of Dynavax Technologies by 4.6% during the 4th quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company’s stock worth $225,000 after buying an additional 771 shares during the last quarter. Finally, Inceptionr LLC acquired a new stake in Dynavax Technologies during the fourth quarter worth $165,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Price Performance

DVAX stock opened at $13.68 on Monday. The business’s 50-day moving average is $13.35 and its two-hundred day moving average is $12.51. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The firm has a market capitalization of $1.70 billion, a P/E ratio of 76.00 and a beta of 1.23. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The business had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. Analysts anticipate that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on DVAX. HC Wainwright restated a “buy” rating and issued a $31.00 price objective on shares of Dynavax Technologies in a report on Friday, February 21st. StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th. The Goldman Sachs Group cut Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their target price for the company from $15.00 to $12.00 in a report on Tuesday, February 11th. Finally, William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.